Abstract:The regenerative function of stem cells is compromised when the proportion of senescent stem cells increases with ageing advance. Therefore, combating stem cell senescence is of great importance for stem cell-based tissue engineering in the elderly, but remains largely unexplored. Osteopontin (OPN), a glycosylated phosphoprotein, is one of the key extracellular matrix molecules in bone tissue. OPN activates various signalling pathways and modulates cellular activities, including cell senescence. However, the role of OPN in stem cell senescence remains largely unknown. This study aims to investigate if OPN modulates cell senescence and bone regenerative function in human adipose-derived mesenchymal stem cells (ASCs), and to determine the underlying mechanisms. We first developed a senescent ASC model using serial passaging until passage 10 (P10), in which senescent cells were characterised by reduced proliferation and osteogenic differentiation capacity compared to P4 ASCs. The conditioned medium from P10 ASCs exhibited a diminished trophic effect on human osteoblasts (HOBs), compared to that from P4 ASCs. P10 ASCs on OPN-coated surface showed rejuvenated phenotype and enhanced osteogenic differentiation. The conditioned medium from P10 ASCs on OPN-coating improved trophic effects on HOBs. OPN regulated the morphology of senescent ASCs, transforming them from a more rounded and flattened cell shape to an elongated shape with a smaller area. These findings demonstrated the effects of OPN in restoring senescent ASCs functions, possibly through a mechanism that involves the modulation of cell morphology, indicating that OPN might hold a great potential for rejuvenating senescent stem cells and could potentially open a new venue for regenerating bone tissue in age-related diseases.
What problem does this paper attempt to address?
The paper primarily investigates the mechanism by which Osteopontin (OPN) reverses the aging state of Adipose-derived Mesenchymal Stem Cells (ASCs) and restores their bone tissue regeneration function. The research background points out that with the extension of human lifespan, health issues brought about by an aging society are becoming increasingly severe, especially age-related bone diseases. The maintenance of bone tissue relies on the coordinated action of various cell types, but as age increases, the regenerative capacity of bone tissue declines, and traditional treatment methods such as autologous bone grafting have limitations. Mesenchymal stem cells, particularly ASCs, due to their self-renewal, differentiation potential, and secretion factors, have shown great potential in bone tissue engineering. However, the age and health status of cell donors can affect the quantity and quality of MSCs, especially the increased proportion of aging cells can reduce their osteogenic differentiation ability.
The paper first established an ASCs aging model through continuous passage, characterized by a significant decline in proliferation and osteogenic differentiation abilities, as well as an increase in senescence-associated β-galactosidase (SA-β-Gal) activity. Subsequently, the research team explored the effects of OPN on aging ASCs. OPN is a glycosylated phosphoprotein present in bone tissue, involved in the activation of multiple signaling pathways and the regulation of cellular activities, including cell aging. Experiments found that when P10 ASCs (i.e., ASCs in an aged state after multiple passages) were cultured on an OPN-coated surface, they exhibited a "rejuvenated" phenotype, including enhanced proliferative ability, improved osteogenic differentiation, and a reduced proportion of SA-β-Gal positive cells. In addition, OPN also improved the morphology of aging ASCs, causing them to change from a flat, round shape to an elongated shape, which may be related to OPN's regulation of cell morphology affecting cell aging.
Further research indicated that OPN reverses the aging of ASCs by altering cell morphology. To verify this hypothesis, researchers used Y27632, a Rho-associated kinase (ROCK) inhibitor that can regulate cell morphology, to treat P10 ASCs. The results showed that Y27632 treatment could also promote changes in cell morphology, reduce the expression levels of cell cycle regulatory genes, decrease the number of SA-β-Gal positive cells, and increase the expression levels of osteogenesis-related genes, similar to the effects of OPN treatment.
In summary, the study reveals the potential of OPN in reversing the aging of ASCs and restoring their bone tissue regeneration function, providing new insights and strategies for using stem cells to treat age-related bone diseases. By regulating cell morphology, OPN can not only improve the biological characteristics of ASCs but may also pave new pathways for bone tissue engineering and regenerative medicine.